We have also explored the therapeutic potential of antibodies or inhibitors targeting the A3/8 complex as a promising avenue for managing hypertriglyceridemia-related genetic conditions such as APOA5 or CREBH deficiencies, as well as for hyperlipidemia in a broader patient population. Here, APOA5 is linked to hypertriglyceridemia.